Update on triple-negative breast cancer: prognosis and management strategies

Triple negative breast cancer (TNBC) is a heterogeneous disease comprehending different orphan breast cancers simply defined by the absence of ER/PR/HER-2. Approximately 15%–20% of all breast cancers belong to this phenotype that has distinct risk factors, distinct molecular features, and a particul...

Full description

Bibliographic Details
Main Authors:	Brouckaert, Olivier, Wildiers, Hans, Floris, Giuseppe, Neven, Patrick
Format:	Online
Language:	English
Published:	Dove Medical Press 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469230/

id	pubmed-3469230
recordtype	oai_dc
spelling	pubmed-34692302012-10-15 Update on triple-negative breast cancer: prognosis and management strategies Brouckaert, Olivier Wildiers, Hans Floris, Giuseppe Neven, Patrick Review Triple negative breast cancer (TNBC) is a heterogeneous disease comprehending different orphan breast cancers simply defined by the absence of ER/PR/HER-2. Approximately 15%–20% of all breast cancers belong to this phenotype that has distinct risk factors, distinct molecular features, and a particular clinical presentation and outcome. All these features will be discussed in this review. The risk of developing TNBC varies with age, race, genetics, breastfeeding patterns, and parity. Some TNBC are very chemo-sensitive and the majority of patients confronted with and treated for TNBC will never relapse. Some (histological) subgroups of TNBC may have good prognosis even in the absence of chemotherapy. Distinct molecular subgroups within TNBC have been defined now as well. In case metastatic relapse occurs, this is usually within 5 years following surgery, and survival following metastatic relapse is shorter compared to other breast cancer subtypes; treatment options are few and responses lack durability. Novel drug targets and new biomarkers are needed to improve breast cancer care for patients presenting with TNBC. Further molecular/biological unraveling of TNBC is needed. Dove Medical Press 2012-09-24 /pmc/articles/PMC3469230/ /pubmed/23071421 http://dx.doi.org/10.2147/IJWH.S18541 Text en © 2012 Brouckaert et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Brouckaert, Olivier Wildiers, Hans Floris, Giuseppe Neven, Patrick
spellingShingle	Brouckaert, Olivier Wildiers, Hans Floris, Giuseppe Neven, Patrick Update on triple-negative breast cancer: prognosis and management strategies
author_facet	Brouckaert, Olivier Wildiers, Hans Floris, Giuseppe Neven, Patrick
author_sort	Brouckaert, Olivier
title	Update on triple-negative breast cancer: prognosis and management strategies
title_short	Update on triple-negative breast cancer: prognosis and management strategies
title_full	Update on triple-negative breast cancer: prognosis and management strategies
title_fullStr	Update on triple-negative breast cancer: prognosis and management strategies
title_full_unstemmed	Update on triple-negative breast cancer: prognosis and management strategies
title_sort	update on triple-negative breast cancer: prognosis and management strategies
description	Triple negative breast cancer (TNBC) is a heterogeneous disease comprehending different orphan breast cancers simply defined by the absence of ER/PR/HER-2. Approximately 15%–20% of all breast cancers belong to this phenotype that has distinct risk factors, distinct molecular features, and a particular clinical presentation and outcome. All these features will be discussed in this review. The risk of developing TNBC varies with age, race, genetics, breastfeeding patterns, and parity. Some TNBC are very chemo-sensitive and the majority of patients confronted with and treated for TNBC will never relapse. Some (histological) subgroups of TNBC may have good prognosis even in the absence of chemotherapy. Distinct molecular subgroups within TNBC have been defined now as well. In case metastatic relapse occurs, this is usually within 5 years following surgery, and survival following metastatic relapse is shorter compared to other breast cancer subtypes; treatment options are few and responses lack durability. Novel drug targets and new biomarkers are needed to improve breast cancer care for patients presenting with TNBC. Further molecular/biological unraveling of TNBC is needed.
publisher	Dove Medical Press
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469230/
_version_	1611915405810466816

Update on triple-negative breast cancer: prognosis and management strategies

Similar Items